PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 9, 20260 citationsOpen Access

Development of bispecific nanobody-derived CARs targeting b-cell leukemia markers: CD19, CD20, and CD22

View Full Paper
JMJoão MarquesMBMartín BonaminoAMAndréa Maranhão

Key Points

  • To develop bispecific nanobody-derived CARs targeting B-cell leukemia markers CD19, CD20, and CD22.
  • Development of bispecific nanobody-derived CARs
  • Targeting specific leukemia markers
  • Presentation at an international symposium
  • New CAR designs implemented for CD19, CD20, and CD22
  • Potential improvements in targeting B-cell leukemia
  • Presented findings at a significant immunobiological event

Abstract

Os autores externos submeteram sua publicação para apresentação de trabalho no evento 'International Symposium on Immunobiologicals', que foi coordenado e organizado pelo Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), da Fundação Oswaldo Cruz.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Marques et al. (2026) studied this question.

synapsesocial.com/papers/69fece83b9154b0b82875dffhttps://doi.org/10.35259/isi.2026_76197
Ask AI
Helpful
Bookmark
Share
View Full Paper